RedHill Biopharma's (RDHL) Movantik Added To Medicare Part D Formulary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
RedHill’s Movantik Added To Medicare Formulary
December 1, 2021 7:04 AM ESTRedHill Biopharma's Movantik Added as Preferred and
Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans
Movantik approved for inclusion as preferred and unrestricted brand on a major National
Medicare Part D formulary serving more than 10 million Americans as of January 1, 2022
-
Movantik's total commercial coverage extends to 152 million American patients' lives and
will grow to 46 million Medicare lives and will increase to over 94% coverage of Medicare Part D... More
